Jim closely worked with the Gilead federal government affairs team to engage federal lawmakers and regulatory officials, highlighting concerns over a recent policy that was exacerbating shortages in R&D resources. He was able to resolve the issue so Gilead could continue its important work. His efforts drew attention from national lawmakers, highlighting the impact supply chain issues can have on drug development in the United States.
Dr. Jim Hartke
